Inicio>>Signaling Pathways>> GPCR/G protein>> Angiotensin Receptor>>L-159282 (MK 996)

L-159282 (MK 996) (Synonyms: MK 996)

Catalog No.GC32569

L-159282 (MK 996) es un antagonista del receptor de angiotensina II no peptÍdico, muy potente, activo por vÍa oral, con actividad antihipertensiva.

Products are for research use only. Not for human use. We do not sell to patients.

L-159282 (MK 996) Chemical Structure

Cas No.: 157263-00-8

Tamaño Precio Disponibilidad Cantidad
1mg
1.057,00 $
Disponible
5mg
2.115,00 $
Disponible
10mg
3.668,00 $
Disponible
20mg
6.426,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.

In the anesthetized chimpanzee, L-159282 (1 mg/kg, iv) produces 100% inhibition of the AII pressor response and is still active (52%) at 24 h. In aortic coarcted (high renin) rats, L-159282 (3 mg/kg, p.o.) reduces blood pressure to normotensive (< 120 mm Hg) levels without reflex tachycardia. This dose of L-159282 reduces blood pressure to approximately the same level as both losartan (3 mg/kg, p.o.) and enalapril (3 mg/kg, p.o.) in this model[1].

[1]. Kivlighn SD, et al. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996. Am J Hypertens. 1995 Jan;8(1):58-66.

Reseñas

Review for L-159282 (MK 996)

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for L-159282 (MK 996)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.